Hong Kong Stock Movement: Cornerstone investors' lock-up lifted, putting heavy pressure on TRANSTHERA-B, stock price plummets 16.6%

Hong Kong Stock Movement TRANSTHERA-B fell 16.60%. Based on recent news, On December 23, several cornerstone investors' shares are about to be unlocked, causing stock prices to generally decline. The unlocking of TRANSTHERA-B's cornerstone investors led to a significant drop in stock price, currently down 11.1%, priced at HKD 150. On December 23, the Hang Seng Index rose slightly, but stocks like TRANSTHERA-B performed poorly due to the unlocking effect. The Hang Seng Index reported 25,838, up 36 points or 0.1%, while TRANSTHERA-B fell 11.08%. On December 22, the market reacted strongly to the upcoming unlocking event, leading to a preemptive drop in TRANSTHERA-B's stock price. Ahead of the unlocking of TRANSTHERA-B's cornerstone investors, market expectations were negative, putting pressure on the stock price. The Hang Seng Index rose slightly, with the overall market performance remaining stable. Stocks with High Trading Volume in the Industry Innovent Biologics fell 0.43%. Based on recent key news: On December 23, Innovent Biologics signed a compliance system construction guidance memorandum with the Shanghai Municipal Market Supervision Administration, aiming to strengthen corporate compliance governance and reduce compliance risks. This cooperation may enhance investor confidence in corporate governance, although the stock price may fluctuate in the short term. On December 23, Innovent Biologics demonstrated the quality and efficiency of Chinese innovative drugs in cross-border BD cooperation, becoming an important force in the global pharmaceutical market. Despite market concerns about homogenized competition, Innovent Biologics' differentiated innovation and international strategy may support its long-term growth. On December 23, Innovent Biologics' product pipeline spans multiple fields, with annual revenue about to exceed HKD 10 billion, becoming an industry leader. Its success in the global market signifies the rise of Chinese innovative pharmaceutical companies, despite short-term stock price fluctuations. The innovation in the pharmaceutical industry is accelerating, with intensified global competition. 3SBio rose 0.69%. Based on recent key news: On December 23, CMB International released a research report recommending a buy on 3SBio, with a target price of HKD 37.58. This rating has boosted market confidence in 3SBio, driving the stock price up. On December 23, the Chinese innovative drug industry is playing a symphony of "value verification" and "payment innovation," with 3SBio achieving significant milestone collections and strategic cooperation, marking the transition of innovative drugs from "transaction heat" to "value reality," enhancing market expectations. On December 22, the MSCI China Healthcare Index rose 51.9%, and after the pharmaceutical sector's correction, valuations and expectations have been rebalanced, creating a better investment layout window for 3SBio. The trend of innovative drugs going overseas continues, supported by policies. Kangfang Biologics fell 1.13%, with a trading volume of HKD 234 million, and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. Stocks with High Market Capitalization in the Industry BeiGene fell 1.39%. Based on recent key news: On December 22, BeiGene recorded a pre-trade of 120,200 shares, with the price per share remaining the same as the previous day, and the transaction amount was 22.25 million yuan. This transaction indicates a stable demand for the stock in the market, despite a slight decline in share price. Source: Economic Information Daily On December 22, the scientific research at Shanghai Synchrotron Radiation Facility continues to drive drug innovation, although it is not directly related to BeiGene, it reflects the technological advancements and innovation potential within the industry. Source: World Scientific Journal No other significant news recently. Industry innovation drives long-term growth potential